Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 and ≤75, male or female.~2. Asymptomatic Infection, Mild, or Common Type of COVID-19.~3. Initial positive test of SARS-Cov-2 within 5 days of randomization.~4. Initial onset of COVID-19 signs/symptoms within 3 days of randomization.~5. The Ct value of SARS-COV-2 nucleic acid test before randomization is ≤ 25, or the Ct value is \>25 and sarS-COV-2 serum IgG and IgM are negative.~Exclusion Criteria:~1. Transnasal high-flow oxygen therapy or non-invasive ventilation, invasive mechanical ventilation, or ECMO is required or anticipated to be urgently required.~2. Prior to current disease episode, any confirmed SARS-CoV-2 infection.~3. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis).~4. Receiving dialysis or have known moderate to severe renal impairment.~5. Known human immunodeficiency virus (HIV) infection.~6. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.s.~7. Oxygen saturation of ≤ 93% on room air obtained at rest within 24 hours prior to randomization..~8. Treatment with antivirals against SARS-CoV-2 within 14 days.~9. Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance.~10. Concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days.~11. Has received or is expected to receive COVID-19 monoclonal antibody, convalescent COVID-19 plasma or other prohibited concomitant medication.~12. Females who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SSD8432 dose 1 (Type: EXPERIMENTAL): SSD8432 dose 1/ritonavir or placebo
- SSD8432 dose 2 (Type: EXPERIMENTAL): SSD8432 dose 2/ritonavir or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).